已發(fā)表的部分文獻(xiàn): 標(biāo)題:Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio.作者:Godler DE, Tassone F, Loesch DZ, Taylor AK, Gehling F, Hagerman RJ, Burgess T, Ganesamoorthy D, Hennerich D, Gordon L, Evans A, Choo KH, Slater HR;雜志名稱:Hum Mol Genet 標(biāo)題:Residual pattern of the hyperintense area on T2-weighted magnetic resonance imaging after initial treatment predicts the pattern and location of recurrence in patients with newly diagnosed glioblastoma.作者:Shimoda Y, Kanamori M, Yamashita S, Shibahara I, Umezawa R, Mugikura S, Jingu K, Saito R, Sonoda Y, Kumabe T, Endo H;雜志名稱:World Neurosurg Epigentek 公司是全球領(lǐng)先的表觀遺傳學(xué)相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開(kāi)發(fā)供應(yīng)商。開(kāi)發(fā)了超過(guò)700多個(gè)專利產(chǎn)品,為表觀遺傳學(xué)方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領(lǐng)域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。